Comparative Efficacy of Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Network Meta-analysis

• DOI: 10.3389/fphar.2021.752048
• Publication Date: 2021-12-08T05:44:11Z
• Authors: Sheng Gao; Yun Zhang; Xun Li; Ge Ge; Jianan Duan; Chunyan Lei; Yue Zeng; Zhaolun Cai; Meixia Zhang
• Keywords: Pharmacotherapy; Retinal Vein

Purpose: This network meta-analysis was conducted to obtain the relative effectiveness of different pharmacotherapy macular edema secondary retinal vein occlusion (RVO) by summarizing all available evidences. Methods: PubMed, Embase, and Cochrane Library databases were searched for relevant randomized controlled trials. The outcomes estimated through a meta-analysis, including mean change in best-corrected visual acuity (BCVA) from baseline, proportion patients who gained ≥15 letters BCVA central thickness (CRT). Results: We identified 15 trials (RCTs) involving 3,431 with RVO our study. Different therapeutic regimens compared three anti-vascular endothelial growth factor (VEGF) agents (ranibizumab, bevacizumab, aflibercept), ranibizumab laser, dexamethasone intravitreal implant, laser. For branch RVO, 0.5 mg monthly [weighted difference (WMD) = 11, 95% confidence intervals (CrI) 3.6 19], 3 + pro re nata (WMD 9.4, CrI 0.43-18) is most effective terms changes or more improvement. anti-VEGF can improve there no significant efficacy among ranibizumab, bevacizumab aflibercept (p > 0.05). Ranibizumab could achieve additional CRT reduction eyes -130, -400 140 WMD -280, -590 16)). Dexamethasone implant 1.7, -4.2 7.1 0.38, -9.8 8.8)) did not show improvement at end 6 months follow-up RVO. Conclusion: In summary, this demonstrated several had equivalent effects on anatomical recovery Only one injection maintain benefit. Patients clinicians choose pharmacotherapies further consideration toward personal factors.